Expansion in global markets, backward integration, and therapeutic focus drive earnings momentum across quarters
Supriya Lifescience Ltd., a global leader in active pharmaceutical ingredients (APIs), has reported its highest-ever annual revenue of ₹696.48 crore in FY25, marking a 22 percent year-on-year growth over ₹570.37 crore posted in FY24. The company also recorded a 57.8 percent increase in profit after tax for the full year, which stood at ₹187.96 crore compared to ₹119.11 crore in the previous year.
EBITDA for the year was ₹260.80 crore, with margins expanding to 37.4 percent from 30.3 percent in FY24. Quarterly earnings also saw strong performance. In Q4 FY25, revenue rose to ₹184.11 crore, up 16.4 percent year-on-year. Profit after tax for the quarter reached ₹50.38 crore, up 38.4 percent from ₹36.40 crore in Q4 FY24.
These results reflect the company’s strategic execution in high-value therapeutic APIs and its growing footprint across 86 global markets.
EBITDA Margin Expansion Reflects Operational Control
For FY25, Supriya Lifescience reported a 712 basis point improvement in EBITDA margin, rising to 37.4 percent from 30.3 percent in the previous year. This is attributed to better product mix, efficiencies in manufacturing, and scale gains from increased exports.
The Q4 margin also improved to 36.7 percent from 35.1 percent in Q4 FY24. The company’s quarterly earnings per share increased to ₹6.29 from ₹4.59 in the same period last year, further reflecting profitability traction.
Strategic Leadership Commentary
Chairman and Whole-Time Director Dr. Satish Wagh commented, “FY25 has been a landmark year for Supriya Lifescience, reflecting the strength of our diversified product portfolio, resilient global operations, and consistent focus on operational excellence. With ₹697 crore in annual revenue and ₹261 crore in EBITDA, we are delivering sustainable growth backed by deep therapeutic capabilities.”
Dr. Wagh emphasized that the company’s focus on anti-histamine, vitamin, anesthetic, and anti-asthmatic APIs continues to support profitability across regulated and semi-regulated markets.
Therapeutic Focus and Market Penetration
Supriya Lifescience maintains a diversified therapeutic base with core focus areas that include antihistamines, anti-allergic medications, anesthetics, and vitamin-based APIs. The company serves more than 1,200 customers globally and operates in 86 countries.
Its strong presence in regulated markets such as Europe, Canada, Brazil, and Southeast Asia is supported by global accreditations from USFDA, EUGMP, PMDA Japan, TGA Australia, WHO, and others.
The company also reported increased penetration in Latin America and emerging regions with backward integrated manufacturing of key intermediates, which improves cost control and product traceability.
Strong Compliance Backed by Global Certifications
Supriya Lifescience’s manufacturing facility in Khed, Ratnagiri is fully cGMP compliant and certified by global regulators including the USFDA, EUGMP, EDQM, Health Canada, and NMPA China. The company holds 14 US Drug Master Files (USDMFs) and eight active Certificates of Suitability (CEPs) for the European market.
Its regulatory strength has been instrumental in forging exclusive contracts with innovator companies and in-house product development partnerships with global Contract Manufacturing Organizations (CMOs).
Key FY25 and Q4 Financials
- FY25 revenue was ₹696.48 crore, up from ₹570.37 crore in FY24
- EBITDA for FY25 reached ₹260.80 crore, compared to ₹172.98 crore last year
- PAT increased to ₹187.96 crore, a growth of 57.8 percent
- PAT margin rose to 27.0 percent from 20.9 percent
- Q4 revenue was ₹184.11 crore, up from ₹158.18 crore
- Q4 PAT stood at ₹50.38 crore, up from ₹36.40 crore, with a margin of 27.4 percent